GlassScriptPhysician profile
Timothy T You
NPI 1326041880
$54,840.71
in general payments reported to CMS, 2019-2025
39 companies · $5,799 in 2025
The $5,799 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,841 · 2020: $3,426 · 2021: $4,387 · 2022: $22K · 2023: $7,360 · 2024: $3,501 · 2025: $5,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,659 · Consulting Fee: $5,515 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,475 · Education: $10.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,659.14 |
| Consulting Fee | $5,515.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,475.00 |
| Education | $10.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $15,524.17 | 2022-2025 | Xipere, Miebo, Xiidra |
| Genentech USA, INC. | $12,928.62 | 2019-2025 | Vabysmo, Susvimo |
| Allergan, INC. | $8,739.28 | 2019-2022 | |
| Alcon Vision LLC | $3,341.16 | 2019-2025 | Rocklatan, Ngenuity, Constellation |
| Regeneron Healthcare Solutions, INC. | $2,322.08 | 2019-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $1,745.60 | 2020-2025 | Acthar |
| Abbvie INC. | $1,640.74 | 2022-2025 | Ozurdex, Vraylar, Lumigan |
| Cardinal Health 108 LLC | $1,575.00 | 2020 | |
| Apellis Pharmaceuticals, INC. | $1,155.34 | 2022-2025 | Syfovre |
| Notal Vision, INC. | $897.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $708.46 | 2019-2021 | |
| Astellas Pharma US INC | $662.24 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $606.51 | 2019-2024 | Yutiq, Iluvien |
| Genentech, INC. | $351.63 | 2019-2025 | Vabysmo, Susvimo |
| Aerie Pharmaceuticals, INC. | $297.53 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Samsara Vision | $296.12 | 2022-2024 | |
| Optos, INC. | $289.47 | 2019 | |
| Ani Pharmaceuticals, INC. | $226.67 | 2024-2025 | Yutiq, Purified Cortrophin Gel, Iluvien |
| Astellas Pharma Global Development | $199.56 | 2024-2025 | Izervay |
| Regeneron Pharmaceuticals, INC. | $161.17 | 2019-2022 | |
| Harrow Eye, LLC | $153.31 | 2023-2025 | Iheezo, Vevye |
| Oyster Point Pharma, INC. | $117.28 | 2022-2023 | Tyrvaya |
| Thrombogenics, INC. | $117.01 | 2019 | |
| Biogen, INC. | $115.76 | 2022-2024 | Byooviz |
| Ivantis, INC | $111.75 | 2020-2021 | |
| Horizon Therapeutics Plc | $100.41 | 2022-2023 | Tepezza |
| Sight Sciences, INC. | $96.61 | 2022 | |
| Coherus Oncology, INC. | $73.85 | 2022-2023 | |
| Neurotech Pharmaceuticals, INC. | $64.14 | 2025 | |
| Eyepoint US, INC. | $59.21 | 2019-2021 | |
| Amgen INC. | $49.70 | 2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $47.75 | 2024-2025 | |
| Rayner Intraocular Lenses Limited | $23.58 | 2025 | Omidria |
| Thea Pharma INC. | $21.13 | 2023 | Iyuzeh |
| Spark Therapeutics, INC. | $19.34 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy You listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.